Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 64

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 64
---
 and corporate governance committee, in accordance with the Nasdaq rules.

Merger Consideration and Exchange Ratio

For a discussion of the merger consideration and the Exchange Ratio, please see the section titled “ The Merger Agreement—Merger Consideration and Exchange Ratio.”

Accounting Treatment of Merger

MIRA will account for the transaction as an asset purchase under the guidance provided in ASC 805-10-55-5 through ASC 805-10-55-9. MIRA concluded that under the applicable rules, the Merger meets the criteria for an asset acquisition rather than a business combination. Neither MIRA nor SKNY has obtained a legal or tax opinion confirming that the Merger qualifies as a reorganization under Section 368(a) of the Code.

Material U.S. Federal Income Tax Consequences of the Merger

This summary is based upon current provisions of the Code, existing Treasury regulations, judicial decisions, and published rulings and administrative pronouncements of the IRS, all in effect as of the date hereof and all of which are subject to differing interpretations or change. Any such change or differing interpretation, which may be retroactive, could alter the tax consequences to SKNY stockholders as described in this summary.

This discussion applies only to SKNY stockholders who hold their SKNY Capital Stock as a “capital asset” within the meaning of Section 1221 of the Code, and does not address all U.S. federal income tax consequences relevant to a SKNY stockholder. In addition, it does not address consequences relevant to SKNY stockholders that are subject to particular U.S. or non-U.S. tax rules, including, without limitation to SKNY stockholders that are:

| ● | brokers,                                                                                    
 dealers or traders in securities; banks; insurance companies; other financial institutions; 
 mutual funds;                                                                               |

| ● | real                                                                                               
 estate investment trusts; regulated investment companies; tax-exempt organizations or governmental 
 organizations;                                                                                     |

| ● | pass-through                                                                               
 entities such as partnerships, S corporations, disregarded entities for federal income tax 
 purposes and limited liability companies (and investors therein);                          |

| ● | persons                                      
 who are not U.S. holders (as defined below); |

| ● | subject                                                
 to the alternative minimum tax provisions of the Code; |

| ● | persons                                                                                          
 who hold their shares as part of a hedge, wash sale, synthetic security, conversion transaction, 
 or other integrated transaction;                                                                 |

| ● | persons                                                     
 that have a functional currency other than